April 18, 2007
SAN FRANCISCO – Leading experts on breast cancer treatment discussed the use and benefits of the new SAVI™ applicator and procedure for cavity-conforming brachytherapy during a seminar held April 12 in San Francisco.

The SAVI device was developed by BioLucent, Inc. The event, which highlighted new advances in breast brachytherapy, took place in conjunction with the 2007 American Society of Breast Disease Annual Symposium.

SAVI offers a single-entry, multi-catheter approach to breast brachytherapy as part of breast-conserving cancer treatment. The applicator combines the tissue-sparing dosimetry of interstitial brachytherapy with the single-entry ease of intracavitary (“balloon”) brachytherapy.

Speakers at the event were:

  • Robert R. Kuske, MD, regarded as a national authority on the radiotherapeutic management of breast cancer. Dr. Kuske is a Clinical Professor at the University of Arizona Health Sciences Center, Phoenix Campus and a physician at Arizona Oncology Services in Scottsdale, Ariz.
  • Coral A. Quiet, M.D., Medical Director of the Arizona Institute for Breast Health and a physician at Arizona Oncology Services in Paradise Valley, Ariz.
  • Victor J. Zannis, M.D., a leading researcher in breast surgery. Dr. Zannis is Medical Director of Breast Care Center of the Southwest in Phoenix, Ariz.

Drs. Kuske and Quiet discussed their early experiences using SAVI. Dr. Zannis presented a breast surgeon’s perspective on the device and procedure.

“SAVI has the potential to make the benefits of brachytherapy available to more women who need treatment for breast cancer,” said BioLucent President Jill Anderson. “As these presentations demonstrated, physicians are recognizing that SAVI represents a significant advance in post-surgical breast radiotherapy.”

The multi-catheter, expandable SAVI applicator is designed to deliver a conformal, precisely targeted dose of radiation. This unique capability may make the benefits of accelerated partial breast irradiation (APBI) available to a larger group of women. It also gives more treatment planning flexibility to the radiation oncologist and physicist.

The April 12 presentations were organized by BioLucent.

BioLucent, Inc. is a women’s health company dedicated to the early detection and treatment of breast cancer. BioLucent also manufactures and markets the MammoPad® breast cushion, a radiolucent foam cushion that breast centers use to provide women with a more comfortable mammogram. By eliminating a major barrier to screening mammography, MammoPad can encourage compliance with recommended screening guidelines, which in turn can help make breast conservation therapy available to more women.

For more information about the company, call (toll-free) 866-460-4141 or access www.BioLucent.com.